Knowthestock.com
CUE - Cue Biopharma Inc
We couldn't determine Recommendation based on the data we have.




Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cue Biopharma Inc (CUE) - https://www.cuebiopharma.com/
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Exchange - NASDAQ
Industry - Research and Development in Biotechnology
Sector - Professional, Scientific, and Technical Services
CEO - Daniel Passeri
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.